Nuket ÖZKAVRUK ELİYATKIN, Kahraman Nesibe ÇETİN

2015 World Health Organization Classification of Pulmonary Tumors “A Valid Classification Until the New Classification”

In 2011, a research panel funded by the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society and European Respiratory Society proposed a variety of significant improvements to all lung tumours prior to lung adenocarcinoma. Furthermore, the recommendations were adopted in this study panel with only minor changes and were identified as the 2015 World Health Organization (WHO) classification of lung tumours. Most of the studies conducted to establish this classification were realised by ‘the IASLC Pathology Committee’. Leading experts in these fields have given their approval to certain subheadings for the organization and have accepted the WHO book. The most recent classification of lung, pleura, thymus and heart tumours was published by the WHO in 2015. Over the last 15 years, the classification of lung cancer has undergone major changes since the WHO classification in 2004 due to the effects of genetic research on lung cancer and important advances in target therapies. In this review article, these changes will be assessed from a pathologist’s perspective.

2015 Dünya Sağlık Örgütü Pulmoner Tümör Sınıflandırması "Yeni Sınıflandırmaya Kadar Geçerli Bir Sınıflama"

2011 yılında Uluslararası Akciğer Kanseri Çalışmaları Derneği (IASLC), Amerikan Toraks Derneği, ve Avrupa Solunum Derneği’nin sponsor olduğu çalışma panelinde, öncelikle akciğer adenokarsinomu olmak üzere tüm akciğer tümörleri için birçok önemli değişiklik önerilmiştir. Bu çalışma panelinde önerilenler, yalnızca minor değişiklikler ile kabul edilerek 2015 Dünya Sağlık Örgütü (DSÖ) akciğer sınıflaması olarak tanımlanmıştır. Bu sınıflamayı oluşturmak için yapılan çalışmaların çoğu, “IASLC’nin Patoloji Komitesi” tarafından gerçekleştirilmiştir. DSÖ kitabının düzenlenmesi ve kabulü için, bu konularda rehber niteliğindeki uzmanlar belli alt başlıklar için onay vermişlerdir. Böylece, DSÖ 2015 yılında, akciğer, plevra, timus ve kalp tümörlerinin en son sınıflamasını yayınlamıştır. Son on beş yıl içinde akciğer kanser genetiği ile ilgili çalışmaların sonuçlarına ve hedef tedavilerinde ortaya çıkan önemli gelişmelere bağlı olarak, bir önceki 2004 DSÖ sınıflamasından sonra akciğer kanser sınıflamasında önemli değişiklikler olmuştur. Bu derleme yazısında, bu değişiklikler patolog gözüyle değerlendirilmeye çalışılacaktır.

PDF

___

1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer; 2015.

2. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and genetics: tumours of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer; 2004.

3. World Health Organization. Histological typing of lung tumours. Geneva: World Health Organization; 1967.

4. World Health Organization. Histological typing of lung tumors. Geneva: World Health Organization; 1981.

5. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, in collaboration with LHS, Countries pf. Histological typing of lung and pleural tumors. Berlin: Springer; 1999.

6. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thoracic Oncol 2011; 6: 244-85.

7. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8: 823-59.

8. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014; 32: 3673-79.

9. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013; 137: 668-84.

10. Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010; 5: 411-4.

11. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012; 136: 163-71.

12. Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, et al. Refining the diagnosis and EGFR status of nonsmall cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010; 5: 436-41.

13. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012; 25: 405-15.

14. Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS, Moreira AL, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol 2012; 25: 1117-27.

15. Kadota K, Nitadori J, Woo KM, Sima CS, Finley DJ, Rusch VW, et al. Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 2014; 9: 1126-39.

16. Kadota K, Yeh YC, Villena-Vargas J, Cherkassky L, Drill EN, Sima CS, et al. Tumor budding correlates with protumor immune microenvironment and is an independent prognostic factor for recurrence of stage I lung adenocarcinoma. Chest 2015; 148: 711-21.

17. Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 2014; 38: 448-60.

18. Kadota K, Nitadori J, Sima CS, Ujiie H, Rizk NP, Jones DR, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. J Thorac Oncol 2015; 10: 806-14.

19. Warth A, Muley T, Kossakowski CA, Goeppert B, Schirmacher P, Dienemann H, et al. Prognostic impact of intraalveolar tumor spread in pulmonary adenocarcinoma. Am J Surg Pathol 2015; 39: 793-801.

20. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. Lyon: International Agency for Research on Cancer; 2005.

21. Wang LC, Wang L, Kwauk S, Woo JA, Wu LQ, Zhu H, et al. Analysis on the clinical features of 22 basaloid squamous cell carcinoma of the lung. J Cardiothorac Surg 2011; 6: 10.

22. Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, et al. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch 2014; 464: 61-8.

23. Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5: 209ra153. doi: 10.1126/scitranslmed.3006802.

24. Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 2014; 9: 273-84.

25. Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Lüer SC, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012; 18: 5773-9.

26. French CA, Kutok JL, Faquin WC, Toretsky JA, Antonescu CR, Griffin CA, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004; 22: 4135-9.

27. Devouassoux-Shisheboran M, Hayashi T, Linnoila RI, Koss MN, Travis WD. A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium. Am J Surg Pathol 2000; 24: 906-16.

28. Niho S, Suzuki K, Yokose T, Kodama T, Nishiwaki Y, Esumi H. Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung. Am J Pathol 1998; 152: 1065-9.

29. Xiao S, Lux ML, Reeves R, Hudson TJ, Fletcher JA. HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. Am J Pathol 1997; 150: 901-10.

30. Anderson T, Zhang L, Hameed M, Rusch V, Travis WD, Antonescu CR. Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. Am J Surg Pathol 2015; 39: 132-9.